The mechanism of synergistic interaction between etoposide and cytarabine

Yakugaku Zasshi

Volumn 122, Issue 7, 2002, Pages 471-480

  Ooi, Kazuya ^a  

^a MIE UNIVERSITY   (Japan)

Author keywords

Ara C; Deoxycytidine kinase; Etoposide; Sequential therapy

Indexed keywords

CYTARABINE; DEOXYCYTIDINE KINASE; ETOPOSIDE; DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES TUMOR; CONTROLLED STUDY; DRUG ACTIVATION; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVITY; INJECTION; INOCULATION; LEUKEMIA; MOUSE; NONHUMAN; TIME; ANIMAL; CELL CYCLE; DRUG ADMINISTRATION; DRUG COMBINATION; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; LEUKEMIA L 1210; METABOLISM; MOUSE STRAIN; PATHOLOGY; REVIEW; STIMULATION;

ANIMALS; CELL CYCLE; CYTARABINE; DEOXYCYTIDINE KINASE; DNA, NEOPLASM; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ETOPOSIDE; HUMANS; INJECTIONS, INTRAPERITONEAL; LEUKEMIA L1210; MICE; MICE, INBRED STRAINS; STIMULATION, CHEMICAL; TIME FACTORS;

EID: 0036632728     PISSN: 00316903     EISSN: None     Source Type: Journal    
DOI: 10.1248/yakushi.122.471     Document Type: Article

References (31)

1. Rivera G., Avery T., Roberts D., Eur. J. Cancer, 11, 639-647 (1975).
2. Dombernowsky P., Nissen N. I., Eur. J. Cancer, 12, 181-188 (1976).
3. Koza I., Balazova E., Ujhazy V., Neoplasma, 27, 691-696 (1980).
4. Ooi K., Ohkubo T., Kawasaki H., Sakurai M., Yakugaku Zasshi, 109, 865-868 (1989).
5. Issell B. F., Crooke S. T., Cancer Treatment Reviews, 6, 107-124 (1979).
6. Schmoll H., Cancer Treatment Reviews, 9, 21-30 (1982).
7. Wozniak A. J., Ross W. E., Cancer Res., 43, 120-124 (1983).
8. Long B. H., Musial S. T., Brattain M. G., Biochemistry, 23, 1183-1188 (1984).
9. Ross W., Rowe T., Glisson B., Yalowich J., Liu L., Cancer Res., 44, 5857-5860 (1984).
10. Long B. H., Musial S. T., Brattain M. G., Cancer Res., 45, 3106-3112 (1985).
11. Pommier Y., Schwartz R. E., Zwelling L. A., Kerrigan D., Mattern M. R., Charcosset J. Y., Jacquemin-Sabion A., Kohn K. W., Cancer Res., 46, 611-616 (1986).
12. Evan J. S., Musser E. A., Bostwick L., Mengel G. D., Cancer Res., 24, 1285-1293 (1964).
13. Finklestein J. Z., Scher J., Karon M., Cancer Chemotherapy, 54, 35-39 (1970).
14. Furth J. J.,Cohen S. S., Cancer Res., 28, 2061-2067 (1968).
15. Major P. P., Egan E.M., Herrick D. J., Kufe D. W., Biochem. Pharmacol., 31, 2937-2940 (1982).
16. Kufe D., Spriggs D., Egan E. M., Munroe D., Blood, 64, 54-58 (1984).
17. Ooi K., Ohkubo T., Kawasaki H., Sakurai M., Yakugaku Zasshi, 110, 673-677 (1990).
18. Roberts D., Hilliard S., Peck C., Cancer Res., 40, 4225-4231 (1980).
19. Ooi K., Ohkubo T., Taniguchi K., Higashigawa M., Kawasaki H., Sakurai M., Hamazaki Y., Jpn. J. Hosp. Pharm., 22, 142-144 (1996).
20. Karon M., Shirakawa S., Cancer Res., 29, 687-696 (1969).
21. Bhuyan B. K., Fraser T. J., Gray L. G., Kuentzel S. L., Neil G. L., Cancer Res., 33, 888-894 (1973).
22. Fietkau R., Friede H., Maurer-Schultze B., Cancer Res., 44, 1105-1113 (1984).
23. Ooi K., Ohkubo T., Kuwabara H., Higashigawa M., Sakurai M., Yakugaku Zasshi, 112, 832-836 (1992).
24. Ooi K., Ohkubo T., Higashigawa M., Kawasaki H., Sakurai M., Jpn. J. Clin. Pharmacol. Ther., 27, 569-573 (1996).
25. Wiley J. S., Jones S. P., Sawyer W. H., Eur. J. Cancer Clin. Oncol., 19, 1067-1074 (1983).
26. Ooi K., Ohkubo T., Kuwabara H., Higashigawa M., Kawasaki H., Kakitoh H., Kagawa Y., Inagaki S., Sumida K., Sakurai M., Cancer Invest., 11, 388-392 (1993).
27. Ooi K., Ohkubo T., Kuwabara H., Higashigawa M., Kawasaki H., Sakurai M., Biol. Pharm. Bull., 19, 1382-1383 (1996).
28. Momparler R. L., Fischer G. A., J. Biol. Chem., 243, 4298-4304 (1968).
29. Durham J. P., Ives D. H., J. Biol. Chem., 245, 2276-2284 (1970).
30. Kufe D. W., Major P. P., Egan E. M., Beardsley G. P., J. Biol. Chem., 255, 8997-9000 (1980).
31. Wang L. M., Kucera G. L., Capizzi R.L., Biochim. Biophys. Acta, 1202, 309-316 (1993).